Immix Biopharma Inc
NASDAQ:IMMX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Immix Biopharma Inc
NASDAQ:IMMX
|
US |
|
NIU Technologies
NASDAQ:NIU
|
CN |
|
E
|
EZZ Life Science Holdings Ltd
ASX:EZZ
|
AU |
|
Hithink RoyalFlush Information Network Co Ltd
SZSE:300033
|
CN |
|
Shanghai Rural Commercial Bank Co Ltd
SSE:601825
|
CN |
|
Alector Inc
NASDAQ:ALEC
|
US |
|
Kesko Oyj
OMXH:KESKOB
|
FI |
|
R
|
Renta 4 Banco SA
F:4RE
|
ES |
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
HK |
|
T
|
Tangshan Sunfar Silicon Industries Co Ltd
SSE:603938
|
CN |
|
S
|
Supreme Infrastructure India Ltd
NSE:SUPREMEINF
|
IN |
Immix Biopharma Inc
Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company is headquartered in Los Angeles, California and currently employs 2 full-time employees. The company went IPO on 2021-12-16. The firm is focused on the development of therapies for patients with cancer and inflammatory diseases. The company is developing a class of tissue-specific therapeutics (TSTx) in oncology and inflammation. The Company’s lead asset, IMX-110, is is a negatively-charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor and induces tumor cell death with an apoptosis inducer controlling tumor micro-environment (TME) normalization technology, which is delivered into the TME. IMX-110, is in clinical trials for solid tumors in the United States and Australia. The Company’s System Multi-Action RegulaTors SMARxT Tissue-Specific platform produces drugs that accumulate at intended therapeutic sites at 3-5 times the rate of conventional medicines. Its Immune Normalization Technology used for inflammatory bowel disease with GLUT1 antibody biomarker targeting coupled with polyphenol poly-kinase inhibitor.
Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company is headquartered in Los Angeles, California and currently employs 2 full-time employees. The company went IPO on 2021-12-16. The firm is focused on the development of therapies for patients with cancer and inflammatory diseases. The company is developing a class of tissue-specific therapeutics (TSTx) in oncology and inflammation. The Company’s lead asset, IMX-110, is is a negatively-charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor and induces tumor cell death with an apoptosis inducer controlling tumor micro-environment (TME) normalization technology, which is delivered into the TME. IMX-110, is in clinical trials for solid tumors in the United States and Australia. The Company’s System Multi-Action RegulaTors SMARxT Tissue-Specific platform produces drugs that accumulate at intended therapeutic sites at 3-5 times the rate of conventional medicines. Its Immune Normalization Technology used for inflammatory bowel disease with GLUT1 antibody biomarker targeting coupled with polyphenol poly-kinase inhibitor.
